Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Sci Rep ; 6: 35854, 2016 10 24.
Article in English | MEDLINE | ID: mdl-27775025

ABSTRACT

Strategies to identify tumors at highest risk for treatment failure are currently under investigation for patients with bladder cancer. We demonstrate that flow cytometric detection of poorly differentiated basal tumor cells (BTCs), as defined by the co-expression of CD90, CD44 and CD49f, directly from patients with early stage tumors (T1-T2 and N0) and patient-derived xenograft (PDX) engraftment in locally advanced tumors (T3-T4 or N+) predict poor prognosis in patients with bladder cancer. Comparative transcriptomic analysis of bladder tumor cells isolated from PDXs indicates unique patterns of gene expression during bladder tumor cell differentiation. We found cell division cycle 25C (CDC25C) overexpression in poorly differentiated BTCs and determined that CDC25C expression predicts adverse survival independent of standard clinical and pathologic features in bladder cancer patients. Taken together, our findings support the utility of BTCs and bladder cancer PDX models in the discovery of novel molecular targets and predictive biomarkers for personalizing oncology care for patients.


Subject(s)
Biomarkers, Tumor/metabolism , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/pathology , Xenograft Model Antitumor Assays/methods , Aged , Animals , Biomarkers, Tumor/genetics , Cell Differentiation/genetics , Female , Flow Cytometry , Gene Expression Regulation, Neoplastic , Humans , Male , Mice, SCID , Middle Aged , Prognosis , Prospective Studies , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/surgery , cdc25 Phosphatases/genetics
2.
Pneumologie ; 69(1): 17-22, 2015 Jan.
Article in German | MEDLINE | ID: mdl-25599139

ABSTRACT

This retrospective case series shows that 45 % of patients aspirated straight after removal of the tracheal cannula. The present case series includes 82 patients with long-term mechanical ventilation (LTMV) admitted to a specialised weaning unit. Aspiration was proven after patients sipped water coloured with patent blue V. Colour was detected with a bronchoscope after passing through the tracheostoma and directed toward the VC. The aspiration rate in this study is in good agreement with other reports in the literature.We could find no significant statistical differences concerning age (p = 0.97), gender (47 % vs. 49), number of bronchoscopies (p = 0.91) and comorbidities (p = 0.326) between patients with and without aspiration. The duration of the stay at the ward and the duration of ventilation as well as the parameter Hb at the time of admission (p = 0.566), CO2(p = 0.288/p = 0.716), HCO3 (p = 0.915/p = 0.612) and CRP (p = 0.402/p = 0.523) at the time of admission and discharge also showed no significant differences.The Kaplan Meier curves show a considerable divergence between patients with and without aspiration. However, the Log Rank Test (p = 0.348) and the univariate Cox Regression (HR 1.4, 95 % CI 0.689 - 2.849) were not significant. We believe that this can be attributed to the event rate, which was too low in our collective. This trend to a higher mortality of patients with aspiration might be due to weakness of the respiratory muscles when there is reduced coughing. Proof of aspiration in these patients is only one aspect of a multidimensional problem. Larger, prospective cohort studies are needed to show whether aspiration can serve as a prognostic marker.


Subject(s)
Hospital Mortality , Length of Stay/statistics & numerical data , Respiratory Aspiration/diagnosis , Respiratory Aspiration/mortality , Ventilator Weaning/mortality , Age Distribution , Aged , Female , Germany/epidemiology , Humans , Incidence , Intensive Care Units , Male , Respiratory Aspiration/etiology , Retrospective Studies , Risk Factors , Sex Distribution , Survival Rate , Ventilator Weaning/adverse effects , Ventilator Weaning/statistics & numerical data
3.
Br J Pharmacol ; 154(4): 797-811, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18536733

ABSTRACT

BACKGROUND AND PURPOSE: As baclofen is active in patients with anxiety disorders, GABAB receptors have been implicated in the modulation of anxiety. To avoid the side effects of baclofen, allosteric enhancers of GABAB receptors have been studied to provide an alternative therapeutic avenue for modulation of GABAB receptors. The aim of this study was to characterize derivatives of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one (rac-BHFF) as enhancers of GABAB receptors. EXPERIMENTAL APPROACH: Enhancing properties of rac-BHFF were assessed in the Chinese hamster ovary (CHO)-Galpha16-hGABA(B1a,2a) cells by Fluorometric Imaging Plate Reader and GTPgamma[35S]-binding assays, and in rat hippocampal slices by population spike (PS) recordings. In vivo activities of rac-BHFF were assessed using the loss of righting reflex (LRR) and stress-induced hyperthermia (SIH) models. KEY RESULTS: In GTPgamma[35S]-binding assays, 0.3 microM rac-BHFF or its pure enantiomer (+)-BHFF shifted the GABA concentration-response curve to the left, an effect that resulted in a large increase in both GABA potency (by 15.3- and 87.3-fold) and efficacy (149% and 181%), respectively. In hippocampal slices, rac-BHFF enhanced baclofen-induced inhibition of PS of CA1 pyramidal cells. In an in vivo mechanism-based model in mice, rac-BHFF increased dose-dependently the LRR induced by baclofen with a minimum effective dose of 3 mg kg(-1) p.o. rac-BHFF (100 mg kg(-1) p.o.) tested alone had no effect on LRR nor on spontaneous locomotor activity, but exhibited anxiolytic-like activity in the SIH model in mice. CONCLUSIONS AND IMPLICATIONS: rac-BHFF derivatives may serve as valuable pharmacological tools to elucidate the pathophysiological roles played by GABAB receptors in the central and peripheral nervous systems.


Subject(s)
Anti-Anxiety Agents/pharmacology , Benzofurans/pharmacology , Receptors, GABA-B/drug effects , Allosteric Regulation/drug effects , Animals , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/chemistry , Baclofen/adverse effects , Baclofen/pharmacology , Benzofurans/administration & dosage , Benzofurans/chemistry , CHO Cells , Cricetinae , Cricetulus , Dose-Response Relationship, Drug , GABA Agonists/adverse effects , GABA Agonists/pharmacology , GTP-Binding Protein gamma Subunits/metabolism , Humans , Male , Mice , Mice, Inbred DBA , Pyramidal Cells/drug effects , Pyramidal Cells/metabolism , Rats , Rats, Wistar , Receptors, GABA-B/metabolism , Reflex/drug effects , Stereoisomerism
4.
Ann Cardiol Angeiol (Paris) ; 54(1): 21-5, 2005 Jan.
Article in French | MEDLINE | ID: mdl-15702907

ABSTRACT

ARVD manifests itself by a wide spectrum of clinical presentations from asymptomatic patients to a broad range of ventricular arrhythmia, extrasystoles, tachycardia, or sudden arrhythmic death which can be the first symptom. It is a major cause for sudden death in young people and sportsmen. In known ARVD the risk of sudden death is not easy to assess from the literature, as its natural history is modulated by the wide variety of antiarrhythmic therapies. Hemodynamically ill tolerated ventricular arrhythmia, left ventricular involvement, sports, a youger age below 35, and uncontrolled therapy seem to predict an adverse outcome for these patients. These data may be helpful to decide for an AICD.


Subject(s)
Arrhythmogenic Right Ventricular Dysplasia/complications , Death, Sudden, Cardiac/etiology , Age Factors , Anti-Arrhythmia Agents/therapeutic use , Arrhythmogenic Right Ventricular Dysplasia/drug therapy , Arrhythmogenic Right Ventricular Dysplasia/genetics , Arrhythmogenic Right Ventricular Dysplasia/physiopathology , Death, Sudden, Cardiac/prevention & control , Electrophysiology , Humans , Myocarditis/complications , Risk Factors , Sports/physiology , Syncope/etiology , Ventricular Dysfunction, Left/complications
5.
FEBS Lett ; 422(2): 146-50, 1998 Jan 30.
Article in English | MEDLINE | ID: mdl-9489994

ABSTRACT

Multiple genetic polymorphisms of the human dopamine D4 receptor (hD4R) have been identified including a 12 bp repeat in exon 1 associated with a psychotic condition called delusional disorder. Competition binding assays revealed minor pharmacological differences between the recombinant A1 (normal) and A2 (delusional) proteins with respect to quinpirole and the antipsychotic clozapine, however no functional differences were detected for receptor activation by dopamine, epinephrine, or norepinephrine. Our results suggest that this polymorphism may only confer susceptibility to delusional disorder in combination with other genetic or environmental factors.


Subject(s)
Receptors, Dopamine D2/genetics , Schizophrenia, Paranoid/genetics , Animals , Antipsychotic Agents/pharmacology , CHO Cells , Clozapine/pharmacology , Cricetinae , Dopamine/pharmacology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Epinephrine/pharmacology , Genetic Variation , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Humans , Kinetics , Norepinephrine/pharmacology , Polymorphism, Genetic , Quinpirole/pharmacology , Receptors, Dopamine D2/biosynthesis , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/physiology , Receptors, Dopamine D4 , Recombinant Proteins/metabolism , Transfection
6.
J Neurochem ; 68(2): 804-12, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9003072

ABSTRACT

The catecholamines dopamine (DA), epinephrine (EP), and norepinephrine (NE) play important roles in learning and memory, emotional states, and control of voluntary movement, as well as cardiovascular and kidney function. They activate distinct but overlapping neuronal pathways through five distinct DA receptors (D1R-D5R) and at least 10 different adrenergic receptors (alpha 1a/b/c, alpha 2a/b/c-1/c-2, and beta 1/beta 2/beta 3). The D4R, which is localized to mesolimbic areas of the brain implicated in affective and emotional behavior, has a deduced amino acid sequence with homology to both adrenergic and dopaminergic receptor subtypes. We report here that DA, EP, and NE all show binding in the nanomolar range to three isoforms of the recombinant human D4R (hD4R): D4.2, D4.4, and D4.7. Submicromolar concentrations of DA, EP, and NE were sufficient to activate hD4R isoforms in two different functional assays: agonist-induced guanosine 5'-O-(3-[35S]thiotriphosphate) binding and modulation of adenylyl cyclase activity. DA was approximately fivefold more potent than EP and NE at the D4R, whereas activation of the human D2R required at least 100-fold higher catecholamine concentrations. Functional activation of the D4R by multiple neurotransmitters may provide a novel mechanism for integration of catecholamine signaling in the brain and periphery.


Subject(s)
Adrenergic alpha-Agonists/pharmacology , Epinephrine/pharmacology , Norepinephrine/pharmacology , Receptors, Dopamine D2/agonists , Adrenergic alpha-Agonists/metabolism , Animals , Binding, Competitive/physiology , CHO Cells/chemistry , CHO Cells/physiology , Colforsin/pharmacology , Cricetinae , Cyclic AMP/metabolism , Dopamine/metabolism , Dopamine/pharmacology , Epinephrine/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Humans , Membrane Proteins/metabolism , Norepinephrine/metabolism , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D4 , Recombinant Proteins/drug effects , Recombinant Proteins/metabolism , Signal Transduction/drug effects , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...